We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Israeli Scientists to Announce Development of Coronavirus Vaccine

By LabMedica International staff writers
Posted on 16 Mar 2020
Over 50 experienced PhD scientists from the Israel Institute for Biological research (IIBR; Ness-Ziona, Israel) are working to produce a vaccine and antibody for the novel coronavirus.

IIBR was established in 1952 as a governmental research institute, founded by a group of scientists from the IDF Science Corps and from academic organizations. More...
Over the years, IIBR has been engaged in R&D in the fields of biology, chemistry, and environmental sciences. Since 1995, it has operated as a government-affiliated unit that research all areas of defense against chemical and biological weapons, including the operation of national laboratories for detection and identification of such threats. IIBR has now been assigned by the Israeli Prime Minister Mr. Benjamin Netanyahu to produce a vaccine and antibody for the novel coronavirus.

According to reports, scientists at IIBR have had a significant breakthrough in understanding the biological mechanism and qualities of the coronavirus and are expected to announce the completion of the development of a vaccine for COVID-19. However, a number of pre-clinical and clinical trials will have to be conducted for months before the vaccination can be deemed as effective or safe to use. Nevertheless, in view of the global emergency over the coronavirus pandemic, the trials could be accelerated to vaccinate a majority of the people who are at the highest risk of contracting the coronavirus.

Related Links:
The Israel Institute for Biological research (IIBR)


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Automated Urinalysis Solution
UN-9000
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image Credit: Adobe Stock

Companion Diagnostics Expand HER2 Testing in Metastatic Gastroesophageal Cancer

Gastroesophageal adenocarcinoma comprises a group of aggressive cancers that are often diagnosed at an advanced stage and carry poor prognoses. Gastric and esophageal cancers rank among the leading causes... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.